Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Marie Sklodowska-Curie Symposium on Cancer Research and Care 2022
19 slides from Aim Immunotech's conference presentation, Sep 9, 2022
Slide 1: Rintatolimod (Ampligen): An Investigational Immunomodulatory Agent Targeted at Cancers of High-Unmet Need
NYSE American: AIM AIMIMMUNO.COM Phone: 352-448-7797 Rintatolimod (Ampligen®): An Investigational Immunomodulatory Agent Targeted at Cancers of High-Unmet Need Christopher McAleer, Ph.D. Deputy Science Officer, AIM ImmunoTech Email: Chris. McAleer@aimimmuno.com Phone: 724-260-6628 Marie Sklodowska-C
Slide 2: Lead Program Ampligen (rintatolimod)
Lead Program Ampligen® (rintatolimod) Significant Opportunity Across Multiple Disease Areas Generally well-tolerated with over 100,000 IV | mmu no-Oncology doses in humans Clinically tested in oncology as a single-agent therapeutic and in combination with other agents Virology Potential in oncology
Slide 3: Ampligen Induces a Wide Range of Immunologic and Anti-tumor Activities
Ampligen® Induces a Wide Range of Immunologic and Anti-tumor Activities Immuno-modulator that selectively activates TLR3 pathway Exclusively activates TRIF adaptor and avoids MyD88 inflammatory pathway used by all other TLRs? Promotes selective attraction of CTLs (Teff) with concomitant increase in
Slide 4: Ampligen: Immuno-Therapy Targeting Multiple Cancers with High-Unmet Need
Ampligen’ Immuno-Therapy Targeting Multiple Cancers with High-Unmet Need
Slide 5: The Critical Unmet Need in Oncology
The Critical Unmet Need in Oncology Current Therapies are Effective but Only in a Subset of Patients, Leaving Many in Need of Better Options United States Statistics Ovarian Cancer’ Pancreatic Cancer’ Breast Cancer’ 21,410 13,770 60,430 48,220 281,550 43,600 New Cases Annually Deaths Annually New Ca
Slide 6: Broad Oncology Pipeline Across Multiple Unmet Needs
Broad Oncology Pipeline Across Multiple Unmet Needs Indications Approach Partner Preclinical Phase 1 Phase2 Phase 3 Approval Ovarian Cancer Chemokine UPMC (Advanced, Recurrent) Modulatory Regimen LUPE CHANGING MEDICINE Colorectal Cancer Chemokine MROSWELL (Metastatic) Modulatory Regimen PARK. Breast
Slide 7: Rintatolimod (Ampligen) Maintenance Therapy after FOLFIRINOX
Rintatolimod (Ampligen®) Maintenance Therapy after FOLFIRINOX Erasmus MC 2afrrg 4 = _1_ Subset = matched controls Qs a p-0.0069 0 12 24 36 Tims In months since start FOLFIRINOX. No. at risk intatollmod a 5 6 2 Contrats a 5 1 a Study population: Patients with metastatic or locally advanced non operab
Slide 8: Rintatolimod (Ampligen) Maintenance Therapy after FOLFIRINOX
Rintatolimod (Ampligen®) Maintenance Therapy after FOLFIRINOX Eras is MC Teafurg a o fe} 0 0 12 24 36 48 Time In months since start FOLFIRINOX: No. at riak ‘Rintatolimod a7 8 10 5 o ‘Controts a 16 2 a o Study population: Patients with metastatic or locally advanced non operable pancreatic cancer aft
Slide 9: Rintatolimod (Ampligen) Maintenance Therapy after FOLFIRINOX
Rintatolimod (Ampligen®) Maintenance Therapy after FOLFIRINOX LAPC Subset of Locally Advanced Pancreatic Cancer (LAPC) 60 Overall Survival since = Start of Folfirinox Progression-free Fe 50 N (months)* survival (months)** £ Mean | Median Mean | Median a) aD Ampligen 5 30.4 34 17.6 14 S 30 Control 5
Slide 10: Long-term Survivors Exhibit Decreased SII and NLR as well as Increased B-Cell Counts
Long-term Survivors Exhibit Decreased SIlIl and NLR as well as Increased B-Cell Counts (B) (C) B-Cells 15 * P 8 . 800 [ 3 3 5 8 g -—— 2 600 i pe i g y q £ i = = a pi ** « 400 i 3 ‘\ m5 E :* al g ; g ) = 200 i i O?Ps 1k a (A) Systemic immune inflammation Index (SII) in short-term survivors (n=9) and
Slide 11: Interim Data in Triple Negative Breast Cancer and Recurrent Ovarian Cancer
Wed ey | Best Response =PD=SD *| . _- J increase in non-target lesions gy: 160+ ee LL 140+ ** PD per RECIST v1.1, continued to have ‘ourreuensive cance cenreR = 120 partial response later @ £ ; . . . s Metastatic Triple Negative Breast Cancer § Ampligen + Intron-A + Celecoxib a Followed by pembroliz
Slide 12: Summary of Recent Ampligen Data Publications
AAGR ee ‘American Association for Cancer Research’ 4999 cancers Annals of Summary of Recent Ampligen Data Publications Negative impact of paclitaxel on human breast tumor microenvironment and its reversal by the combination of interferon-a with TLR3 agonist rintatolimod Initial results of a phase II
Slide 13: Ampligen: SARS-CoV-2 (COVID-19)
Ampligen’ SARS-CoV-2 (COVID-19)
Slide 14: COVID-Induced Chronic Fatigue (Long COVID)
Fatigue | Brain Fog COVID-Induced Chronic Fatigue (Long COVID or ‘Long Haulers’) Amended ongoing open-label AMP-511 study in ME/CFS to include up to 20 long COVID subjects Currently treating long COVID subjects Salm buninetech Chronic Illness Following COVID-19 Chronic illness following recovery is
Slide 15: AMP-511 Preliminary Data: Post-COVID Condition of Fatigue Over Time
AMP-511 Preliminary Data: Post-COVID Condition of Fatigue Over Time ue Over Time Patient 1 Patient 2 Patient 3 Patient 4 | Wk6 Wk12 BSL Wk6 Wk12 BSL Wk6 Wk12 BSL Wk6 Wk12 Ini y to exercise or 10.0 10.0 7.0 8.0 5.0 4.0 10.0 8.0 7.0 9.0 7.0 8.0 active [Fatigue RS 6.0 6.0 3.0 30) 9.0 8.0 7.0 8.0 7.0 7.
Slide 16: AMP-511 Preliminary Data: Post-COVID Condition of Fatigue
AMP-511 Preliminary Data: Post-COVID Condition of Fatigue B Baseline B Baseline O Week 12 1.5 Week 12 = a a | = Oo Patient Questionnaire Score ° a o pe a e € ee e s es —e e e Relative change oO oO oO a Source: Preliminary unpublished data from Hunter Hopkins Center. Pl: Dr. Lapp 16
Slide 17: Antiviral Activity of Ampligen
Antiviral Activity of Ampligen Virus Genome (Virus) Model Virus Genome (Virus) Model Double-Stranded DNA [Single-Stranded (-) RNA . Herpes Simplex Type 2 Guinea pig, in vivo protection 23. Influenza, Avian HSN1 |Cynomolgus macaque; in vivo protection vaccine adjuvant Herpes Simplex Type 2 Mouse, in
Slide 18: Summary
Summary e Ampligen has shown promise as an immunomodulatory adjuvant in multiple cancers (Colorectal, Ovarian, TNBC) and as a solely administered therapy in melanoma as well as following FOLFIRINOX in pancreatic cancer (metastatic and LAPC) ° Over 750 patients treated, and 100,000 IV doses indicate
Slide 19: Christopher McAleer, Ph.D.
NYSE American: AIM Christopher McAleer, Ph.D. Deputy Science Officer, AIM ImmunoTech Email: Chris. McAleer@aimimmuno.com Phone: 724-260-6628 AlMImmuno.com 19
AIM ImmunoTech — Marie Sklodowska-Curie Symposium on Cancer Research and Care 2022 on 6ix